Icatibant

This tender, originating from Italy and sourced via ted, is for the procurement of 'Icatibant'. Icatibant is a specific pharmaceutical product, known to be used in the treatment of hereditary angioedema. The contracting authority, likely a healthcare provider or public health institution in Italy, is seeking to secure a supply of this medication. This procurement is critical for ensuring patient access to essential treatments. Typical requirements for a pharmaceutical tender of this nature would include strict adherence to quality standards (e.g., Good Manufacturing Practice - GMP), specific dosage forms and concentrations, packaging requirements, expiry date management, and secure supply chain logistics. Bidders will be expected to provide evidence of regulatory approval (e.g., from the European Medicines Agency or Italian regulatory authorities), product specifications, and a robust distribution plan. The tender documentation will detail the required quantities, delivery locations, and evaluation criteria, which will likely focus on product quality, reliability of supply, and economic competitiveness. The aim is to ensure a consistent and safe supply of Icatibant for patients in Italy.